Archives of Pharmacal Research最新文献_第2页

Retraction Note: MiR-338-5p ameliorates pathological cardiac hypertrophy by targeting CAMKIIδ 注：MiR-338-5p通过靶向CAMKIIδ改善病理性心肌肥厚。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2025-01-02 DOI: 10.1007/s12272-024-01530-0

Kailong Li, Yuedong Lin, Cong Li

引用次数: 0

Effects of fluconazole on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypes 氟康唑对不同CYP2C9基因型塞来昔布及其羧酸代谢物药动学的影响

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-12-27 DOI: 10.1007/s12272-024-01531-z

Chang-Keun Cho, Pureum Kang, Choon-Gon Jang, Yun Jeong Lee, Jung-Woo Bae, Chang-Ik Choi, Seok-Yong Lee

{"title":"Effects of fluconazole on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypes","authors":"Chang-Keun Cho, Pureum Kang, Choon-Gon Jang, Yun Jeong Lee, Jung-Woo Bae, Chang-Ik Choi, Seok-Yong Lee","doi":"10.1007/s12272-024-01531-z","DOIUrl":"10.1007/s12272-024-01531-z","url":null,"abstract":"<div>This study aimed to investigate the effects of fluconazole, a moderate inhibitor of CYP2C9 and CYP3A4, on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypes. A total of thirty-nine healthy Korean male volunteers were divided into three different CYP2C9 genotype groups (CYP2C9*1/*1, *1/*3 and *3/*3 genotypes) and were enrolled in the celecoxib alone trial, celecoxib with fluconazole trial, or both. In the celecoxib alone trial, participants received a single oral dose of 200 mg celecoxib. In the celecoxib with fluconazole trial, participants received 300 mg fluconazole on day 1, 150 mg fluconazole once daily for four consecutive days (day 2–5), and a coadministration of 200 mg celecoxib with 150 mg fluconazole on day 6. Plasma concentrations of celecoxib and celecoxib carboxylic acid were determined by using HPLC–MS/MS. In the CYP2C9*1/*1 genotype group, fluconazole treatment increased AUCinf of celecoxib by 2.61-fold, and decreased CL/F by 60.4% (both p < 0.001). In the CYP2C9*1/*3 genotype group, fluconazole treatment increased AUCinf of celecoxib by 2.44-fold (p < 0.001), prolonged t1/2 by 1.36-fold (p < 0.05), and decreased CL/F by 60.4% (p < 0.001). Fluconazole treatment increased AUCinf of celecoxib by 2.23-fold, prolonged t1/2 by 1.64-fold, and decreased CL/F by 53.8% in the subject with CYP2C9*3/*3 genotype. Cmax of celecoxib carboxylic acid significantly decreased in CYP2C9*1/*1 and *1/*3 genotypes (p < 0.01 and p < 0.05, respectively), following fluconazole treatment, whereas AUCinf showed no significant changes in any CYP2C9 genotype group. In conclusion, fluconazole affected the pharmacokinetics of celecoxib in different CYP2C9 genotypes.</div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 3","pages":"224 - 233"},"PeriodicalIF":6.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunosenescence and age-related immune cells: causes of age-related diseases 免疫衰老和与年龄有关的免疫细胞：与年龄有关的疾病的原因。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-12-26 DOI: 10.1007/s12272-024-01529-7

Nam-Hee Kim, So-Jin Sim, Hong-Gyu Han, Jeong-Hyuk Yoon, Yong-Hyun Han

引用次数: 0

Ideal animal models according to multifaceted mechanisms and peculiarities in neurological disorders: present and challenges 理想的动物模型，根据多方面的机制和特点在神经系统疾病：目前和挑战。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-12-18 DOI: 10.1007/s12272-024-01527-9

Shrawani Lamichhane, Jo-Eun Seo, Ji Hoon Jeong, Sooyeun Lee, Sangkil Lee

{"title":"Ideal animal models according to multifaceted mechanisms and peculiarities in neurological disorders: present and challenges","authors":"Shrawani Lamichhane, Jo-Eun Seo, Ji Hoon Jeong, Sooyeun Lee, Sangkil Lee","doi":"10.1007/s12272-024-01527-9","DOIUrl":"10.1007/s12272-024-01527-9","url":null,"abstract":"<div>Neurological disorders, encompassing conditions such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), pose a significant global health challenge, affecting millions worldwide. With an aging population and increased life expectancy, the prevalence of these disorders is escalating rapidly, leading to substantial economic burdens exceeding trillions of dollars annually. Animal models play a crucial role in understanding the underlying mechanisms of these disorders and developing effective treatments. Various species, including rodents, non-human primates, and fruit flies, are utilized to replicate specific aspects of human neurological conditions. However, selecting the ideal animal model requires careful consideration of its proximity to human disease conditions and its ability to mimic disease pathobiology and pharmacological responses. An Animal Model Quality Assessment (AMQA) tool has been developed to facilitate this selection process, focusing on assessing models based on their similarity to human conditions and disease pathobiology. Therefore, integrating intrinsic and extrinsic factors linked to the disease into the study's objectives aids in constructing a biological information matrix for comparing disease progression between the animal model and human disease. Ultimately, selecting an ideal animal disease model depends on its predictive, face, and construct validity, ensuring relevance and reliability in translational research efforts.</div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 1","pages":"62 - 88"},"PeriodicalIF":6.9,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Three new xanthones and other anti-inflammatory components from the aerial parts of Hypericum beanii 从金丝桃地上部分离得到三种新的山酮类及其它抗炎成分。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-12-18 DOI: 10.1007/s12272-024-01526-w

Wei Ma, Fu-Cai Ren, Xue-Ru Wang, Ning Li

{"title":"Three new xanthones and other anti-inflammatory components from the aerial parts of Hypericum beanii","authors":"Wei Ma, Fu-Cai Ren, Xue-Ru Wang, Ning Li","doi":"10.1007/s12272-024-01526-w","DOIUrl":"10.1007/s12272-024-01526-w","url":null,"abstract":"<div>Hypericum beanii, a traditional folk medicine plant, has been employed in treating various inflammation-related diseases. In this study, three new prenylated xanthones, named beanigenin A (1), beanigenin B (2), and beanigenin C (3), along with twenty-five known compounds (4–28), were isolated from the aerial parts of H. beanii. The new xanthones were elucidated based on modern spectroscopic experiments, including nuclear magnetic resonance spectroscopy (NMR) techniques, high-resolution electrospray ionization mass spectroscopy (HR-ESI-MS), and electronic circular dichroism (ECD). All the compounds were evaluated for their anti-inflammatory effects by measuring their inhibitory effect on nitric oxide (NO) production in LPS-stimulated RAW 264.7 macrophages. Our findings showed that compounds 1–10, 12, 14, 21–23, 26, and 28 displayed significant anti-inflammatory effects, with IC50 values ranging from 0.82 to 9.71 μM. The MOE software was utilized to conduct an in silico evaluation of the potential inhibitory activity of the three new xanthones against inducible NO synthase (iNOS) and cyclooxygenase 2 (COX-2) proteins. The results indicated that the three new xanthones demonstrated a high binding affinity with both iNOS and COX-2 proteins.</div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 1","pages":"89 - 101"},"PeriodicalIF":6.9,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cell membrane chromatography relative competitive method for the accurate determination of relative KD values of drug-receptor interactions 细胞膜色谱相对竞争法准确测定药物受体相互作用的相对KD值。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-12-10 DOI: 10.1007/s12272-024-01525-x

Panpan Lei, Weina Ma, Jiapan Gao, Bingxi Ren, Xiaoyu Ma, Yuxiu Zhang, Xinyue Su, Jinna Liang, Langchong He

{"title":"Cell membrane chromatography relative competitive method for the accurate determination of relative KD values of drug-receptor interactions","authors":"Panpan Lei, Weina Ma, Jiapan Gao, Bingxi Ren, Xiaoyu Ma, Yuxiu Zhang, Xinyue Su, Jinna Liang, Langchong He","doi":"10.1007/s12272-024-01525-x","DOIUrl":"10.1007/s12272-024-01525-x","url":null,"abstract":"<div>The specific binding of a drug to the receptor is a prerequisite for its action. The equilibrium dissociation constant (KD) is an important parameter for measuring the strength of drug-receptor interactions. Cell membrane chromatography (CMC) is a powerful way to determine the KD value; however, the common disadvantage is that the attenuation of biological activity with the analysis process leads to corresponding errors in comparing KD values of a series of drugs. Therefore, it is of practical significance to analyze the relative KD values of drugs for the same membrane receptor under the same conditions. We developed a CMC relative competitive method to determine the relative KD values of drugs through simultaneous injection of the control compound and analyte in each analysis, circumventing the error in KD values of drugs due to the attenuation of the biological activity of the CMC column. The results showed that the KD values of CD147 antagonists and MRGPRX2 agonists determined using the CMC relative competitive method correlated well with the KD values obtained via frontal analysis and stepwise frontal method using the CD147h (MRGPRX2h)/CMC system. Critically, the biological activities of the CD147 antagonists and MRGPRX2 agonists were significantly correlated with KD values measured using the CMC relative competitive method. Therefore, the CMC relative competitive method can accurately and efficiently evaluate the relative KD values of drugs and effectively predict the differences in pharmacological activity between a series of drugs, which has important guiding significance in the development of targeted drugs.</div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 1","pages":"102 - 114"},"PeriodicalIF":6.9,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142805920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring β-caryophyllene: a non-psychotropic cannabinoid's potential in mitigating cognitive impairment induced by sleep deprivation 探索β-加里叶烯：一种非精神类大麻素在减轻睡眠不足引起的认知障碍方面的潜力。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-12-09 DOI: 10.1007/s12272-024-01523-z

Cher Ryn Lim, Satoshi Ogawa, Yatinesh Kumari

{"title":"Exploring β-caryophyllene: a non-psychotropic cannabinoid's potential in mitigating cognitive impairment induced by sleep deprivation","authors":"Cher Ryn Lim, Satoshi Ogawa, Yatinesh Kumari","doi":"10.1007/s12272-024-01523-z","DOIUrl":"10.1007/s12272-024-01523-z","url":null,"abstract":"<div>Sleep deprivation or sleep loss, a prevalent issue in modern society, is linked to cognitive impairment, leading to heightened risks of errors and accidents. Chronic sleep deprivation affects various cognitive functions, including memory, attention, and decision-making, and is associated with an increased risk of neurodegenerative diseases, cardiovascular issues, and metabolic disorders. This review examines the potential of β-caryophyllene, a dietary non-psychotropic cannabinoid, and FDA-approved flavoring agent, as a therapeutic solution for sleep loss-induced cognitive impairment. It highlights β-caryophyllene's ability to mitigate key contributors to sleep loss-induced cognitive impairment, such as inflammation, oxidative stress, neuronal death, and reduced neuroplasticity, by modulating various signaling pathways, including TLR4/NF-κB/NLRP3, MAPK, Nrf2/HO-1, PI3K/Akt, and cAMP/PKA/CREB. As a naturally occurring, non-psychotropic compound with low toxicity, β-caryophyllene emerges as a promising candidate for further investigation. The review underscores the therapeutic potential of β-caryophyllene for sleep loss-induced cognitive impairment and provides mechanistic insights into its action on crucial pathways, suggesting that β-caryophyllene could be a valuable addition to strategies aimed at combating cognitive impairment and other health issues due to sleep loss.</div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 1","pages":"1 - 42"},"PeriodicalIF":6.9,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biological insights and therapeutic potential of Glycyrrhiza uralensis and its bioactive compounds: an updated review 乌拉尔甘草及其活性化合物的生物学研究进展及其治疗潜力。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-12-03 DOI: 10.1007/s12272-024-01522-0

Sibhghatulla Shaikh, Khurshid Ahmad, Jeong Ho Lim, Syed Sayeed Ahmad, Eun Ju Lee, Inho Choi

{"title":"Biological insights and therapeutic potential of Glycyrrhiza uralensis and its bioactive compounds: an updated review","authors":"Sibhghatulla Shaikh, Khurshid Ahmad, Jeong Ho Lim, Syed Sayeed Ahmad, Eun Ju Lee, Inho Choi","doi":"10.1007/s12272-024-01522-0","DOIUrl":"10.1007/s12272-024-01522-0","url":null,"abstract":"<div>The recent resurgence of traditional medicines, driven by a renewed interest in the medicinal use of plant extracts, has garnered significant scientific attention for their therapeutic efficacy in treating a wide range of diseases. Glycyrrhiza species, commonly known as licorice, are widely recognized both as herbal remedies and as natural sweeteners. Among these, Glycyrrhiza uralensis stands out for its exceptional therapeutic potential, particularly in enhancing muscle regeneration, slowing muscle aging, and promoting skeletal muscle myogenesis. This review explores the traditional uses and biological effects of G. uralensis, highlighting the biological significance of its bioactive constituents, such as saponins and flavonoids. The hepatoprotective, antibacterial, antioxidant, anticancer, antidiabetic, antiobesity, anti-inflammatory, skeletal muscle-enhancing and cardiovascular effects of G. uralensis are reviewed, along with its toxicity and safety profile. Additionally, we propose directions for future clinical and scientific investigations, advocating for using G. uralensis as a natural therapeutic agent. The primary aim of this review is to contribute to the incorporation of this ancient medicine into modern clinical practice.</div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"47 12","pages":"871 - 892"},"PeriodicalIF":6.9,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring NNMT: from metabolic pathways to therapeutic targets 探索 NNMT：从代谢途径到治疗目标。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-11-28 DOI: 10.1007/s12272-024-01519-9

Jeongwoo Park, Eun Jin Shin, Tae Hyun Kim, Ji Hye Yang, Sung Hwan Ki, Keon Wook Kang, Kyu Min Kim

{"title":"Exploring NNMT: from metabolic pathways to therapeutic targets","authors":"Jeongwoo Park, Eun Jin Shin, Tae Hyun Kim, Ji Hye Yang, Sung Hwan Ki, Keon Wook Kang, Kyu Min Kim","doi":"10.1007/s12272-024-01519-9","DOIUrl":"10.1007/s12272-024-01519-9","url":null,"abstract":"<div>Cellular metabolism-related epigenetic modulation plays a pivotal role in the maintenance of cellular homeostasis. Nicotinamide N-methyltransferase (NNMT) serves as a crucial link between cellular metabolism and epigenetics by catalyzing nicotinamide methylation using the universal methyl donor S-adenosyl-L-methionine. This direct connection bridges the methylation-mediated one-carbon metabolism with nicotinamide adenine dinucleotide levels. Numerous studies have revealed tissue-specific differences in NNMT expression and activity, indicating that its varied physiological and pathological roles depend on its distribution. In this review, we provide an overview of the NNMT involvement in various pathological conditions, including cancer, liver disease, obesity, diabetes, brain disease, pulmonary disease, cardiovascular disease, and kidney disease. By synthesizing this information, our article aims to enhance our understanding of the cellular mechanisms underlying NNMT biology related to diverse diseases and lay the molecular groundwork for developing therapeutic strategies for pharmacological interventions.</div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"47 12","pages":"893 - 913"},"PeriodicalIF":6.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142738302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Curcumin targets CXCL16-mediated podocyte injury and lipid accumulation in diabetic kidney disease treatment 姜黄素在糖尿病肾病治疗中靶向 CXCL16 介导的荚膜细胞损伤和脂质蓄积。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2024-11-28 DOI: 10.1007/s12272-024-01521-1

Ying Chen, Jun Tao, Yijun He, Xudong Hou, Ji Fang, Jiebo Huang, Li Wang, Junlong Shen, Bingbing Zhu, Niansong Wang, Aili Cao

{"title":"Curcumin targets CXCL16-mediated podocyte injury and lipid accumulation in diabetic kidney disease treatment","authors":"Ying Chen, Jun Tao, Yijun He, Xudong Hou, Ji Fang, Jiebo Huang, Li Wang, Junlong Shen, Bingbing Zhu, Niansong Wang, Aili Cao","doi":"10.1007/s12272-024-01521-1","DOIUrl":"10.1007/s12272-024-01521-1","url":null,"abstract":"<div>Among the complications of diabetes, diabetic kidney disease (DKD) frequently emerges, typified by the detrimental effects on renal function, manifesting through inflammation, dysregulated lipid metabolism, and harm to podocytes. Existing research underscores the significance of the soluble form of C-X-C chemokine ligand 16 (CXCL16) within the context of renal impairments. However, whether CXCL16 is involved in the pathogenesis of DKD remains elusive. We report that CXCL16 levels in the serum and kidneys of individuals with DKD were elevated and correlated with various lipid parameters. The expression of CXCL16 in human podocytes subjected to high glucose or palmitic acid induction and exogenous CXCL16 administration in these cells were examined. Higher CXCL16 levels were linked to abnormal lipid metabolism. Exogenous CXCL16 administration induced lipid droplets, microfilament disorganization, apoptosis, oxidative stress, and inflammation, inhibited PPAR γ, up-regulated COX2 expression, and inhibited Nrf2 translocation in podocytes. Molecular analysis revealed that Curcumin (Cur), a polyphenolic compound derived from Curcuma longa and an Nrf2 agonist, targets the ATP-binding pocket of CXCL16, inhibiting its kinase activity. Meanwhile, Cur therapy alleviated podocyte injury, lipid accumulation, improved glomerulopathy, and reduced albuminuria. Furthermore, after silencing CXCL16 expression in podocytes using siRNA, the effects of exogenous CXCL16 were nullified, and Cur no longer exhibited any significant impact. Thus, CXCL16 participates in the pathogenesis of DKD. Inhibition of CXCL16 has shown promising results in experimental models, suggesting its beneficial effects in ameliorating DKD.</div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"47 12","pages":"924 - 939"},"PeriodicalIF":6.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142738301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0